Overview

HER2-Peptide Vaccination of Patients With Solid Tumors

Status:
Completed
Trial end date:
2018-07-13
Target enrollment:
Participant gender:
Summary
Investigation of peptide vaccination targeting HER2/neu in patients with metastasized breast or gastric cancer with moderate HER2/neu expression.
Phase:
Phase 1
Details
Lead Sponsor:
Technische Universität München
Treatments:
Cyclophosphamide
Imiquimod
Sargramostim
Vaccines